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CObjectives: Bosentan, a dual endothelin receptor antagonist (ERA),
was the first oral drug approved for the treatment of pulmonary arterial
hypertension (PAH), a rare disease with poor prognosis. In 2004 the
Australian Department of Health agreed to fund bosentan on the phar-
maceutical benefits scheme (PBS) on the condition that a registry was
established to monitor mortality: if the observed mortality rate was
higher than that claimed in the original funding submission then the
price of bosentan would be reduced tomaintain the original incremen-
tal cost-effectiveness ratio (ICER). This article presents the economic
implications of the bosentan patient registry (BPR).Methods: An exist-
ing economic model was updated using the results of the BPR.
Results: Participation rates were high and the BPR collected 821 pa-
tient years of follow-up on 528 patients. Based on the observed raw
mortality a 23.7% price reduction would have been needed tomaintain O
scen
al So
oi:10.1016/j.jval.2011.02.1177he original ICER in idiopathic PAH patients. After allowing for the
igher risk patients actually treated in Australia, a 13.5% reduction in
osentan price would have been required. In 2008, however, sitaxen-
an, a new oral ERA PAH treatment was listed on the PBS at a 15%
iscount to bosentan. On the basis of cost-minimization, bosentanwas
orced to reduce its price to that of sitaxentan. After this price reduction
he ICER for bosentan was similar to that originally proposed and
ence, no additional price reductionwas sought by the Pharmaceutical
enefits Advisory Committee (PBAC). Conclusions: The bosentan PAH
egistry provided a useful mechanism for monitoring the cost-effec-
iveness of bosentan after funding approval.
eywords: bosentan, pharmaceutical funding, risk-share agreement.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Risk-sharing agreements in which price is linked to ongoing data
collection have been widely discussed but few practical case stud-
ies are available [1–8]. Bosentan, a dual endothelin receptor antag-
onist (ERA) was the first oral drug approved for the treatment of
pulmonary arterial hypertension (PAH), a rare disease with poor
prognosis. In 2004 the Australian Department of Health agreed to
fund bosentan on the pharmaceutical benefits scheme (PBS) on
the condition that a registry was established tomonitor mortality.
The future price of bosentan would be adjusted based on the re-
sults of the registry [9]. If the observed mortality rate was higher
han that claimed in the original funding submission then the
rice of bosentanwould be reduced tomaintain the original incre-
ental cost-effectiveness ratio (ICER). This article presents the
conomic implications of the bosentan patient registry (BPR).
Methods
The registry agreement
At the time of the Pharmaceutical Benefits Advisory Committee
(PBAC) recommendation, two short-term randomized controlled
trials were available that indicated bosentan improved intermedi-
ate outcomes of hemodynamics, 6-minute walk distance (6MWD),
* Address correspondence to: John Wlodarczyk, PhD, 10 Mirral Cre
E-mail: john@jwcs.com.au.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.and time to clinical worsening [10,11]. Links between changes in
intermediate outcomes and long-term survival were not well es-
tablished. Therefore, an economic model based on long-term fol-
low-up of these trials was developed that assumed bosentan
would reduce mortality from 26.6% to 5.2% per annum; thereby
increasing life expectancy from 2.8 years to 6.7 years. The resul-
tant ICER was considered high but acceptable in the presence of a
risk-sharing agreement. The bosentan funding agreement re-
quired Actelion to establish a registry to monitor the survival of
bosentan-treated patients. Mortality rates from the registry were
then to be substituted into the original model and the price of
bosentan adjusted to maintain the original ICER.
The registry protocol was designed to collect sufficient data to
allow a precise estimate of mortality rates. In this way any large
deviations from the target could be identified or ruled out with
confidence. The registry was funded by Actelion, run by an aca-
demic center, and overseen by an advisory board. Results of the
registry were to be reported to the PBAC. Some of the ethical and
logistical problems encountered in establishing and running a reg-
istry have been reported previously in Owen et al. [12].
Results of the registry
The registry had excellent response from clinicians and patients
with 821 patient years of follow-up on 528 patients and a partici-
t, New Lambton, NSW 2305 Australia.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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962 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 6 1 – 9 6 3pation rate of approximately 70%. Refusal rates were extremely
low and non-participation resulted largely from operational fac-
tors in rolling out centers for the study [13].
Themortality rate in idiopathic PAH (iPAH)was 11.8%per annum
95%CI, 8.8–14.8) comparedwith the 5.2% predicted by the economic
odel. Thepatients enrolled in the registry, however,were older and
admore severe disease than those in the clinical trials onwhich the
greement was based. The registry data clearly revealed that older
atientswithmore severe disease (WorldHealthOrganization Func-
ional Class IV [WHO FC IV]) had higher mortality rates [13].
The age and severity-specific mortality rates for the registry
ere used to calculate an adjusted mortality rate. This was done
y calculating age and severity-specific mortality rates from the
PR and then lowering the percent of older and more severe pa-
ients to that seen in the randomized controlled trials (RCTs). This
djusted estimate of mortality was 8.8%.
Originally the focus of the economic model and the registry agree-
ent were on iPAH patients. However, associated PAH [systemic scle-
osis] patients, or APAH-SSc, formed a larger proportion of the treat-
entpopulation thanexpected: 42%of registrypatientswereofAPAH-
Sc etiology compared with 21% of the RCT populations. Associated
AH-SSc patients were generally thought to have a worse prognosis
han iPAH patients with annualmortality rates in the order of 45% [14-
6]. The observedAPAH-SScmortality rate from the BPRwas 16.6%.
Pricing implications
Using the same assumptions as the original model [9], the ob-
served rawmortality rate of 11.8% per annumwould have resulted
in an ICER of AUD$80,735 per life year gained and a 23.7% price
reduction would have been necessary to maintain the original
ICER of AUD$62,267. After weighting to the trial population (mor-
tality rate of 8.8%), the ICER was reduced to AUD$69,811 and a
13.5% reduction in bosentan price would have been required. In-
cluding APAH-SSc patients in the model would have further im-
proved the ICER to AUD$64,427 per life year gained (Table 1).
Bosentanwas followedby anumber of competitors in themarket
(epoprostenol sodium [Flolan, GlaxoSmithKline, Research Triangle
Park,NC], iloprost, sitaxentan,ambrisentan, sildenafil [Revatio, Pfizer
Inc, New York, NY]). In a process independent of the registry, sitax-
entan, another oral ERA was listed on the PBS in 2008 at a 15% price
discount to bosentan (for patients with iPAH/APAH-SSc, and FC III).
The PBAC then requested a price decrease for bosentan tomatch the
sitaxentan price on the basis that they were similar in effectiveness.
Actelion agreed to this request and no further price reductions were
sought by the PBAC via the risk-share agreement.
Table 1 – Cost-effectiveness of bosentan versus usual care
Annual mortality rate
Bosentan Usual care Bosentan
iPAH
Original model 5.2% 25% $220,666
Observed mortality 11.8% 25% $160,939
Adjusted mortality* 8.8% 25% $185,121
SSc
Versus Kawut et al. [15]
Observed 16.6% 45% $127,904
Adjusted 14.12% 45% $141,763
Weighted iPAH (58%) and
SSc (42%)
Observed 13.6% 34.3% $146,729
Adjusted 11.3% 34.3% $165,679
ICER, incremental cost-effectiveness ratio; iPAH, idiopathic pulmona
* Adjusting age and severity to that of the key clinical trials.Discussion
Risk-sharing arrangements have been described as warranties [17].
harmaceutical companies demonstrate their confidence in a product
yagreeingtoreducepriceorrefundpayments if theproductdoes itnot
ive up to expectations [18]. If agreements can be designed effectively,
ncertainty about long-term cost-effectiveness can be reduced and so
llows timely access to effective but high cost drugs.
The quality of the evidence gathered after listing is crucial to
ny risk-share agreement. The two most basic requirements in
ssessing the validity of data fromcohort studies such as registries
re that the participants are representative of the target popula-
ion and a high rate of follow-up. The BPR had a high participation
ate. The 100% follow-up for survival via the national death index
rovides confidence in its results.
AmajorcriticismoftheBPRdatawasthepotential forsildenafiladd-
n or switch to Flolan; either of whichmight improve survival in some
atients. If thiswasthecasethenitcouldbearguedthattheregistrywas
ot directly reflecting the survival benefits of bosentan. This was un-
ikely to havehad amajor influence on the BPR. First, the use of add-on
herapy was low and switching to Flolan was rare; second, there was
imited evidence onwhether add-on sildenafil improved survival.
Conclusions
TheBPRprovideddataonpatientswith iPAHandAPAH-SSc, their treat-
ment, and their survival which supported continued public funding of
bosentan. Risk-sharing arrangements that rely onmonitoring objective
measurable outcomes can play a valuable role in establishing cost-ef-
fectiveness.
Acknowledgments
The authors would like to acknowledge the support of Adriana
Platona of the Pharmaceutical Evaluation Scheme, Department of
Health and Ageing, Commonwealth Government, Australia, and
the Bosentan Advisory Board Members and Clinicians.
Sources of financial support: No funding or support has been
received for this manuscript. The original bosentan model and
bosentan registry was sponsored by Actelion Pharmaceuticals.
Glen Pater is employed by Actelion Pharmaceuticals Australia.
JohnWlodarczyk hasworked as a consultant for Actelion Pharma-
ceuticals. Christopher M Reid is employed by Monash University;
the university was contracted to manage the BPR. He does not
have a financial arrangement with Actelion Pharmaceuticals.
d on annual mortality rates estimated from the registry.
l cost Years of life ICER
cost/YOL
ndard Diff Bosentan Standard Diff
18,332 $202,334 6.108 2.823 3.285 $61,594
18,332 $142,607 4.589 2.823 1.766 $80,735
18,332 $166,789 5.212 2.823 2.389 $69,811
$9165 $118,739 3.403 1.480 1.923 $61,738
$9165 $132,598 3.745 1.480 2.265 $58,530
13,585 $133,143 4.020 2.119 1.901 $70,040
13,773 $151,906 4.510 2.152 2.358 $64,427
erial hypertension; SSc, systemic sclerosis; YOL, year of life.base
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ERRATUM
Thearticle “Economic Evaluationof ReamedversusUnreamed IntramedullaryNailing in PatientswithClosedandOpenTibial Fractures: Results
from theStudy to Prospectively Evaluate Reamed IntramedullaryNails in PatientswithTibial Fractures (SPRINT),” byBriel et al.waspublished in
Value inHealth 2011;14:450–7. The correct author by-line is as follows: TheSPRINT Investigators. The full listing of the SPRINT Investigatorswho
took part in the collaboration of this article can be found in the Acknowledgments section of the article.
ERRATUM
The article “Economic Impact of Nonpersistence with Antidepressant Treatment in the Adult Population of Quebec: A Comparative
Cost-Effectiveness Approach,” by Béland et al (Value in Health 2011;14:492-8), was published with an incorrect Figure 1. The correct
Figure 1 is shown below.
Fig. 1 – Mean total costs and effectiveness of alternative antidepressant treatment.
